FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 678 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Program Helps Medically Underserved, Minority Cancer Survivors Be More Active July 3, 2024 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 Does Too Much Fructose Help Colorectal Cancers Grow? October 29, 2021 England: Smoking responsible for twice as many cancers in most deprived... August 2, 2021 Load more HOT NEWS A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... As Rates of Some Cancers Increase in Younger People, Researchers Search... Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated...
